SI

SI-BONE IncNASDAQ SIBN Stock Report

Last reporting period 30 Sep, 2024

Updated 18 Nov, 2024

Last price

Market cap $B

0.602

Micro

Exchange

XNAS - Nasdaq

SIBN Stock Analysis

SI

Uncovered

SI-BONE Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-8/100

Low score

Market cap $B

0.602

Dividend yield

Shares outstanding

34.986 B

SI-BONE, Inc. engages in the provision of implantable devices used in the surgical treatment of the sacropelvic anatomy. The company is headquartered in Santa Clara, California and currently employs 357 full-time employees. The company went IPO on 2018-10-17. The firm is focused on the development of implantable devices used in the surgical treatment of sacro-pelvic anatomy. Its invasive surgical implant system, iFuse, is used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. Its iFuse Implant System includes a series of triangular titanium implants and the instruments developed to enable surgeons to perform the procedure. Its iFuse system, which includes its implants and instruments, is designed to address the shortcomings of alternative treatments, including open surgery, non-surgical management, and screw-based and other minimally invasive stabilization and fusion procedures. Its iFuse-3D design allows the surgeons to fill the implant with ground-up bone before implantation, which accelerates bone through-growth and biological fixation. The company also provides other technologies for its surgeons other than iFuse and iFuse-3D.

View Section: Eyestock Rating